Publications by authors named "Latonia Miller"
Article Synopsis
- Pulmonary arterial hypertension (PAH) is a serious lung condition caused by changes in small blood vessels that lead to increased pressure in the pulmonary artery, and this is often linked to problems in the cells lining these vessels.
- A key factor, DLL4, helps maintain healthy blood vessels through NOTCH1 signaling, and its inhibition is connected to the advancement of PAH, but the exact process is not fully understood.
- Research indicates that restoring DLL4/NOTCH1 signaling or inhibiting the AKT pathway can help reverse harmful changes in the blood vessels seen in PAH, offering potential treatment strategies using compounds like leniolisib.
Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary disease characterized by pathologic vascular remodeling of small pulmonary arteries. Endothelial dysfunction in advanced PAH is associated with proliferation, apoptosis resistance, and endothelial to mesenchymal transition (EndoMT) due to aberrant signaling. DLL4, a cell membrane associated NOTCH ligand, plays a pivotal role maintaining vascular integrity.
View Article and Find Full Text PDF